Breaking News

LEO Pharma Acquires AstraZeneca Assets

Licenses two dermatology products for $115 million upfront

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

LEO Pharma has entered an agreement with AstraZeneca to acquire the global license to tralokinumab in skin diseases and the exclusive license to brodalumab in Europe. Tralokinumab, an anti-IL-13 monoclonal antibody, has completed a Phase IIb study for the treatment of patients with atopic dermatitis. Brodalumab is an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis.   AstraZeneca will receive $115 million upfront and is eligible t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters